FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First Line Ph+ ALL AJMC The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Analysis: The peptide problem: Hype is outrunning the evidence McMaster News 2026 FDA Peptide Reclassification Purefico Medspa and Therapy